Outcome evaluation of the opioid agonist maintenance treatment in Iran

Drug and Alcohol Review

Volumn 33, Issue 2, 2014, Pages 186-193

  Esmaeili, Hamid Reza ^a   Ziaddinni, Hassan ^b   Nikravesh, Mohammad Rafee ^c   Baneshi, Mohammad Reza ^d   Nakhaee, Nouzar ^e  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Harm reduction; Human; Iran; Opioid related disorders rehabilitation; Patient dropout statistics and numerical data

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; FEMALE; HARM REDUCTION; HEALTH STATUS; HUMAN; IRAN; MALE; MENTAL HEALTH; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS/REHABILITATION; PATIENT DROPOUT/STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

HARM REDUCTION; HUMAN; IRAN; OPIOID-RELATED DISORDERS/REHABILITATION; PATIENT DROPOUT/STATISTICS AND NUMERICAL DATA;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HEALTH STATUS; HUMANS; IRAN; MALE; MENTAL HEALTH; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84897606357     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/dar.12112     Document Type: Article

References (24)

1. Wu Z, Clark N. Scaling up opioid dependence treatment in low- and middle-income settings. Bull World Health Organ 2013;91:82-82A.
2. UNODC. World drug report 2010. Vienna: United Nations Office on Drugs and Crime, 2010.
3. Nakhaee N, Divsalar K, Meimandi MS, Dabiri S. Estimating the prevalence of opiates use by unlinked anonymous urine drug testing: a pilot study in Iran. Subst Use Misuse 2008;43:513-520.
4. Razzaghi EM, Movaghar AR, Green TC, Khoshnood K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J 2006;3:1-13.
5. Laudet AB. The case for considering quality of life in addiction research and clinical practice. Addict Sci Clin Pract 2011;6:44-55.
6. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005;28:321-329.
7. Ministry of Health & Medical Education of Iran. Findings of Piloting of Methadone maintenance Therapy. Office of Substance Abuse Prevention and Treatment (2005). Available at: http://www.sapto.hbi.ir/kindex4.htm (accessed February 2013) [Persian].
8. Padaiga Z, Subata E, Vanagas G. Outpatient methadone maintenance treatment program. Quality of life and health of opioid-dependent persons in Lithuania. Medicina (Kaunas) 2007;43:235-241.
9. United Nations Office on Drugs and Crime UNODC. Evaluation of substance use treatment programmes. 2009. [accessed on April 2011] (Available at:: http://www.unodc.org/ddt-training/treatment/%20VOLUME%20D/Topic%203/1.VolD_Prog_Eval.pdf).
10. Noori R, Narenjiha H, Aghabakhshi H, Habibi G, Khoshkrood Mansoori B. Methadone maintenance therapy outcomes in Iran. Subst Use Misuse 2012;47:767-773.
11. Jefford M, Stockler MR, Tatersall MHN. Outcomes research: what is it and why does it matter? Intern Med J 2003;33:110-118.
12. Mohsenifar S, Mostashari GH, Vazirian M. Opiate dependence treatment protocol with agonist drugs, 2nd edn. Tehran, Tehran: Department of Substance Abuse Prevention and Treatment, Ministry of Health, 2008.
13. Connock M, Juarez-Garcia A, Jowett S, etal. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assesst 2007;11:1-171.
14. Azizi A, Borjali A, Golzari M. The effectiveness of emotion regulation training and cognitive therapy on the emotional and addictional problems of substance abusers. Iran J Psychiat 2010;2:60-65.
15. Yousefy AR, Ghassemi GR, Sarrafzadegan N, Mallik S, Baghaei AM, Rabiei K. Psychometric properties of the WHOQOL-BREF in an Iranian adult sample. Community Ment Health J 2010;46:139-147.
16. Montazeri A, Harirchi AM, Shariati M, Garmaroudi G, Ebadi M, Fateh A. The 12-item General Health Questionnaire (GHQ-12): translation and validation study of the Iranian version. Health Qual Life Outcomes 2003;13:1-66.
17. Gossop M. Treatment outcomes: what we know and what we need to know. London: National Treatment Agency for Substance Misuse, NHS, 2005.
18. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst 2008;(2):CD002207.
19. Jaffee WB, Trucco E, Levy S, Weiss RD. Is this urine really negative? A systematic review of tampering methods in urine drug screening and testing. J Subst Abuse Treat 2007;33:33-42.
20. Mancino M, Curran G, Han X, Allee E, Humphreys K, Booth BM. Predictors of attrition from a national sample of methadone maintenance patients. Am J Drug Alcohol Abuse 2010;36:155-160.
21. Che Y, Assanangkornchai S, McNeil E, etal. Predictors of early dropout in methadone maintenance treatment program in Yunnan province, China. Drug Alcohol Rev 2010;29:263-270.
22. Lawrinson P, Ali R, Buavirat A, etal. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction 2008;103:1484-1492.
23. Ball SA, Carroll KM, Canning-Ball M, Rounsaville BJ. Reasons for dropout from drug abuse treatment: symptoms, personality, and motivation. Addict Behav 2006;3:320-330.
24. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003;98:441-452.